Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)
April 3, 2023 03:13 PM EDTUpdated April 5, 08:58 AM
Deals
Manufacturing

Gink­go part­ners up with Sen­si­ble Biotech­nolo­gies to forge mR­NA man­u­fac­tur­ing plat­form

Tyler Patchen

News Reporter

Since the suc­cess­ful, glob­al re­lease of mR­NA-based Covid-19 vac­cines, the mR­NA plat­form has be­come a top fo­cus for bio­phar­ma com­pa­nies. Gink­go Bioworks’ lat­est part­ner­ship looks …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times